We have updated our privacy policy and terms & conditions. Find out more here.
4
 

GSK China Bribery Scandal Gets Sex Video Twist

By International Business TimesStock MarketsJun 30, 2014 06:40AM GMT Add a Comment
 
AA
+
-

By Reuters - Glaxosmithkline (LONDON:GSK) on Sunday confirmed the existence of an intimate video recording of its former China head, Mark Reilly, which the Sunday Times reported kicked off a bribery investigation that has damaged the drugmaker's business in China.

GSK China Bribery Scandal Gets Sex Video TwistGSK China Bribery Scandal Gets Sex Video Twist

The Sunday Times said the recording was shot without Reilly's knowledge or consent at his Shanghai flat and showed the Briton, who is separated from his wife, with his Chinese girlfriend.

It was not clear who shot the video or with what motivation. The video was emailed to top GSK executives in March 2013, the newspaper said.

A GSK spokesman confirmed the tape existed but did not comment on how it related to the alleged bribery scandal.

In July 2013, Chinese police accused Britain's biggest drugmaker of transferring as much as 3 billion yuan ($482 million) through travel agencies to bribe doctors and officials.

Reuters was not independently able to verify the link between the tape and the bribery case.

Chinese police filed corruption charges against Reilly last month. The Briton, who has been barred from leaving China, could face decades in prison. (Full Story)

Reilly has not been reachable for comment while his lawyer has declined to talk to the media. Reilly's whereabouts are unknown.

China's investigation into GSK and its scrutiny of numerous other foreign and local drugs companies have frightened foreign pharmaceutical executives so much that some fear they could be jailed and have asked their lawyers if they should temporarily leave the country.

GSK, which described the bribery allegations as "shameful" when they came to light last year, said on Sunday that it was continuing to cooperate fully with Chinese authorities on the ongoing investigation.

"The issues relating to our China business are very difficult and complicated," it added in a statement.

© Reuters/Toby Melville. The headquarters of GlaxoSmithKline, manufacturer of the cancer-treating drug Bexxar, which is being discontinued due to disappointing profits.

The bribery case has hit GSK's sales in China, as buyers have shied away from doing business with the company and GSK itself has revamped its sales and marketing model.

Bribery allegations involving GSK have come to light since then in other countries and GSK is now investigating claims that bribes were also paid to doctors in Poland, Iraq, Jordan and Lebanon.

Last month, Britain's Serious Fraud Office launched a formal criminal investigation into GSK.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data .

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Add a Comment

 

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Glaxosmithkline
 
 
 
Are you sure you want to delete this chart?
 
 
 
Are you sure you want to delete this chart?
 
 
 

Successfully Reported

Thank you. This comment has been flagged for a moderator.
_touchLoadingMsg